1-[4-(1-Pyrrolidinylcarbonyl)phenyl]-3-(Trifluoromethyl)-4,5,6,7-Tetrahydro-1h-Indazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-[4-(1-Pyrrolidinylcarbonyl)phenyl]-3-(Trifluoromethyl)-4,5,6,7-Tetrahydro-1h-Indazole
• 英文别名: pyrrolidin-1-yl-[4-[3-(trifluoromethyl)-4,5,6,7-tetrahydroindazol-1-yl]phenyl]methanone
• 化学式: C₁₉H₂₀F₃N₃O
• 分子量: 363.4
• InChiKey: PMXYSSZJPIWCHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  38.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]benzoic acid 、 N,N'-羰基二咪唑 、 四氢吡咯 在 silica 、 乙酸乙酯 、 petroleum ether 作用下， 以 二氯甲烷 为溶剂， 反应 1.25h， 以to give the title compound as a yellow oil (51 mg, 50%)的产率得到1-[4-(1-Pyrrolidinylcarbonyl)phenyl]-3-(Trifluoromethyl)-4,5,6,7-Tetrahydro-1h-Indazole
  参考文献：
  名称：

  Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine

  摘要：

  提供式(I)的化合物和盐，以及药物组合物，用于医学用途，例如治疗由谷氨酸受体功能降低或失衡所介导的疾病或病情，如精神分裂症或认知障碍。

  公开号：

  US20090118280A1

文献信息

• Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine
  申请人：Harrison Stephen

  公开号：US20090118280A1

  公开（公告）日：2009-05-07

  Compounds of formula (I) and salts are provided: along with pharmaceutical compositions, uses in medicine, e.g., treating disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment.

  提供式(I)的化合物和盐，以及药物组合物，用于医学用途，例如治疗由谷氨酸受体功能降低或失衡所介导的疾病或病情，如精神分裂症或认知障碍。
• COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE
  申请人：GLAXO GROUP LIMITED

  公开号：EP1996555A1

  公开（公告）日：2008-12-03
• UPREGULATING BDNF LEVELS TO MITIGATE MENTAL RETARDATION
  申请人：LAUTERBORN JULIE

  公开号：US20080139472A1

  公开（公告）日：2008-06-12

  This invention provides methods of preserving, improving, or restoring cognitive function in mammal having one or more mutations in the FMR1 gene (e.g. at risk for or having fragile x syndrome), where the methods involve the brain derived neurotrophic factor (BDNF) level or activity in the brain of said mammal. In certain embodiments the methods involve administering one or more AMPA potentiators (e.g., ampakines) to the mammal in an amount sufficient to increase BDNF levels in the brain of the mammal.
• Modulation of AMPA/kainate Receptors for the Treatment of Hypoglycemia
  申请人：Vanderklish Peter

  公开号：US20200397751A1

  公开（公告）日：2020-12-24

  Methods for modulating the levels of glucagon and blood glucose of a mammal are provided. In the subject methods, a positive allosteric modulator of AMPA/kainate receptors is administered to a host. The subject methods find use in applications where it is desired to increase one or both of the glucagon and blood glucose levels in a mammalian host. The subject methods find use in applications where it is desired to decrease the size, or breadth, of the circadian range of blood glucose levels in a mammalian host. The subject methods also find use in applications where it is desired to decrease the frequency, severity, or occurrence of hypoglycemia in a mammalian host. Finally, the subject method finds use in applications where it is desired to decrease the frequency, severity, or occurrence of nocturnal hypoglycemia in a mammalian host, particularly that which occurs in diabetics as a result of therapy with insulins or insulin analogs or other glucose lowering agents, or combinations of such agents.
• US7566735B2
  申请人：——

  公开号：US7566735B2

  公开（公告）日：2009-07-28